Our case adds to these reported scenarios, explores the use of burosumab in adult-onset disease, and also highlights that modest FGF-23 elevations in CKD may still exert physiologically inappropriate phosphaturic effects when urinary losses remain excessive despite normal or low serum phosphate. Here, FGF23 is linked to chronic kidney disease.